Successful analysis of epidermal growth factor receptor (*EGFR*) mutations in advanced non--small-cell lung cancer (NSCLC) has provided many patients with *EGFR* mutation-positive disease with the opportunity to receive optimal, targeted treatments.^[@R1],[@R2]^ Tumor tissue is considered the preferred definitive standard sample type for *EGFR* mutation analysis^[@R3]^; however, for many patients, this sample type is not available (\~10--15% from author's clinical experience, and \~23% in the United Kingdom in 2011).^[@R4]^ A molecular-based treatment decision in these patients can therefore be problematic, not only at diagnosis but also at progression, to detect resistance mutations (e.g., T790M) in those who experience disease progression after first-line treatment with EGFR tyrosine kinase inhibitors (TKIs).

Consequently, focus has turned to evaluating the use of surrogate sample types for *EGFR* mutation analysis, the aim of which is to identify the molecular characteristics of tumors from patients who do not have tumor tissue samples.^[@R5]--[@R7]^ One alternative sample type is circulating-free tumor DNA (ctDNA), which is obtained through less invasive methods to source tumor DNA, such as plasma or serum samples. The available evidence for the use of ctDNA for the analysis of *EGFR* mutations is encouraging, a brief review of which is given below.

In 2009, results were published from a large Spanish study which assessed *EGFR* mutation detection in 164 ctDNA samples from the serum of patients with *EGFR* mutation-positive NSCLC as determined from tumor tissue testing.^[@R8]^ Peptide nucleic acid clamp analysis identified *EGFR* mutations in 97 ctDNA samples, a sensitivity of 59.2%. A Chinese study of 35 matched ctDNA and tumor tissue samples also published in 2009 successfully analyzed all ctDNA samples using digital polymerase chain reaction (PCR).^[@R9]^ Subsequent to the publication of these studies, a review published by Aung et al.10 discussed the current status and future potential of *EGFR* mutation testing from ctDNA and concluded that plasma ctDNA would be a viable alternative/additional source of DNA, particularly as advances in PCR technology had allowed the analysis of point mutations in *EGFR*, *KRAS*, *BRAF*, and *PIK3CA* genes from ctDNA isolated from patients' serum or plasma.^[@R11]--[@R14]^ The 2011 publication by Liu et al.^[@R15]^ reported the successful *EGFR* mutation analysis of 86 matched plasma-derived ctDNA and formalin-fixed, paraffin-embedded samples using a Scorpion-amplification refractory mutation system (ARMS). Of the 40 tumor samples identified as *EGFR* mutation-positive, 27 were correctly identified in ctDNA, a sensitivity of 67.5%. More recently, *EGFR* mutation testing of 194 serum-derived ctDNA samples was undertaken as part of a preplanned, exploratory analysis of the Japanese subset of the IPASS study.^[@R5]^ *EGFR* mutations (tested using the ARMS-based DxS *EGFR* mutation Test Kit \[DxS, Manchester, UK\]) were successfully detected in all 194 ctDNA samples, with sensitivity of 43.1%. Moreover, in the 22 patients where mutations were identified in ctDNA and tumor samples, the mutation subtypes were identical in 21 cases. Ongoing real-world studies are also evaluating the utility of plasma ctDNA-based *EGFR* mutation testing compared with tumor DNA. The noninterventional ASSESS study (Europe and Japan)^[@R16]^ and interventional IGNITE study (Asia-Pacific region and Russia)^[@R17]^ are non-comparative studies of *EGFR* mutation status in patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histologies. Concordance between *EGFR* mutation status obtained through tissue/cytology and blood (plasma)-based testing is a primary and secondary objective of the ASSESS and IGNITE studies, respectively. Results from these large, international studies will help establish whether plasma is a suitable, less invasive sample type for reliably determining the *EGFR* mutation status of patients with advanced NSCLC, thus informing the use of this sample type in patients without available/evaluable tumor samples.

One study which has explored per-protocol the use of plasma ctDNA alongside the more traditional tumor tissue for *EGFR* mutation analysis is the phase IV, prospective, open-label, multicenter, single-arm, first-line study of the EGFR TKI gefitinib in Caucasian patients with *EGFR* mutation-positive, advanced NSCLC (NCT01203917). The efficacy and tolerability results of this study have been published previously.^[@R18]^ Briefly, first-line gefitinib was effective in this patient population, as assessed by objective response rate (ORR; 70%, 95% confidence interval \[CI\], 60.5--77.7%), and supported by disease control rate (91%), median progression-free survival (PFS, 9.7 mo), and median overall survival (19.2 mo).^[@R18]^ First-line gefitinib was well tolerated, with adverse events consistent with the characterized tolerability/safety profile for gefitinib in previous studies.^[@R19]--[@R22]^

Patients with NSCLC initially entered the screening phase of the study (*n* = 1060), and eligible patients were progressed to enrollment on the basis of tumor tissue availability and a positive *EGFR* mutation status. Here, we report a comparison of baseline tumor *EGFR* mutation status in all screened patients with evaluable results for baseline plasma. Further analyses compared plasma-derived ctDNA *EGFR* mutation status in duplicate baseline plasma samples from the same patient to evaluate reliability of methodology in non-tumor samples. Post hoc, exploratory analyses of efficacy (ORR and PFS) according to tumor-derived DNA and plasma-derived ctDNA *EGFR* mutation status (and mutation subtype) are also reported.

MATERIALS AND METHODS
=====================

Study Design and Patients
-------------------------

Full details of this study (NCT01203917) have been published previously.^[@R18]^ Briefly, the gefitinib follow-up measure study was a prospective, open-label, multicenter, single-arm study to characterize the efficacy, safety, and tolerability of gefitinib (250 mg/d) as first-line treatment of Caucasian patients with activating, sensitizing, *EGFR* mutation-positive, locally advanced, or metastatic NSCLC. Patient eligibility criteria have been published previously^[@R18]^ and included mandatory provision of tumor samples and duplicate plasma samples for *EGFR* mutation testing at baseline; in addition, optional plasma samples were collected at disease progression (see below for *EGFR* mutation subtype eligibility criteria).

All patients provided written, informed consent, including provision for collection of tumor and plasma samples for biomarker analyses. Study approval was obtained from independent ethics committees at each institution. The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation/Good Clinical Practice, applicable regulatory requirements, and AstraZeneca's policy on bioethics.

Assessments
-----------

Tumor assessment by computed tomography scan was performed every 6 weeks. The primary end point of the study, ORR (complete response plus partial response) by investigator assessment, was determined by the Response Evaluation Criteria In Solid Tumors^[@R23]^ version 1.1. PFS (secondary end point; time from start of study treatment to date of objective tumor progression \[excluding clinical deterioration without evidence of objective progression\]) was also determined by Response Evaluation Criteria In Solid Tumors 1.1. Preplanned exploratory objectives included a comparison of baseline tumor *EGFR* mutation status with evaluable results for baseline plasma, a comparison of plasma-derived ctDNA *EGFR* mutation status in duplicate baseline plasma samples (plasma 1 and 2 samples), and a comparison of baseline and progression plasma samples, from the same patient. Post hoc exploratory analyses included efficacy of gefitinib according to tumor and plasma *EGFR* mutation (and mutation subtype) status.

DNA Extraction and *EGFR* Mutation Analysis
-------------------------------------------

One tumor sample (mandatory) and two plasma samples (mandatory; plasma 1 and plasma 2) were collected from each patient at baseline (screening) for DNA extraction and *EGFR* mutation analysis. An optional plasma sample was collected at disease progression.

Whole blood samples were collected into venous blood collection tubes using ethylenediaminetetraacetic acid as anticoagulant. Samples were mixed thoroughly and plasma isolated within 2 to 4 hours of sample collection by centrifugation at approximately 2000 *g* for 10 minutes (at 4°C or room temperature for pre-chilled samples). Once isolated, plasma samples were centrifuged again (as above), before transferring into cryovials and freezing at −70°C within 4 hours of collection. Samples were not thawed until the time of processing.

A central laboratory (LabCorp, Durham, NC) performed DNA extraction and mutation analysis of both the tumor and plasma samples. Tumor DNA was extracted using the Qiagen QIAamp DNA Mini Kit (Qiagen, Crawley, UK). whereas ctDNA was extracted from plasma using the Qiagen QIAamp Circulating Nucleic Acid Kit (Qiagen). Sample processing details, including modifications to processes, are shown in Supplementary Appendix Table 1 (Supplementary Digital Content 1, <http://links.lww.com/JTO/A638>).

*EGFR* mutation status of all samples was assessed using a Scorpion ARMS-based *EGFR* mutation detection kit (Therascreen *EGFR* RGQ PCR kit; Qiagen, Crawley, UK), which detects 29 mutations across the *EGFR* gene. For tumor samples, all mutations in the kit were analyzed. Methodological and technical details for *EGFR* mutation testing, including modifications to tumor/ctDNA analysis kit instructions and data quality control details, are shown in Supplementary Appendix Table 1 (Supplementary Digital Content 1, <http://links.lww.com/JTO/A638>). A comparison of the Qiagen kit used for ctDNA *EGFR* mutation analysis in the current study and the previous version of the DxS kit used in the IPASS study^[@R19],[@R22]^ are shown in Supplementary Appendix Table 2 (Supplementary Digital Content 1, <http://links.lww.com/JTO/A638>).

*EGFR* mutation status was assigned to baseline tumor samples according to agreed eligibility criteria: positive, more than or equal to one activating, sensitizing *EGFR* mutation with no ineligible mutations; positive ineligible, more than or equal to one ineligible mutation (exon 20 point mutations T790M; S768I; exon 20 insertions, either alone or in combination with another ineligible mutation or a sensitizing mutation \[see Douillard et al.^[@R17]^ appendix\]); negative, no mutations detected; and unknown, no mutation results available (exhaustion of samples, poor quality, or low DNA yield).

Plasma samples were analyzed for exon 19 deletions, L858R point mutation, and the T790M point mutation only. The following *EGFR* mutation status was assigned to individual plasma samples: positive, more than or equal to 1 mutation (L858R, exon 19 deletions \[19 different mutations\], and T790M); negative, no mutations were detected; and unknown, no mutation results available (no sample or poor quality).

Statistical Analysis
--------------------

Data were analyzed using a data cutoff (August 15, 2012) at 6 months after the last patient had started study treatment. ORR (primary end point) was calculated from investigator data and summarized in the full analysis set (FAS; all screened patients with an eligible, positive *EGFR* mutation status who received ≥1 dose of gefitinib), with 95% CIs (Wilson score intervals). PFS was estimated with 95% CIs (FAS) using Kaplan-Meier methods and Greenwood's formula (Greenwood 1926)^24^ (PFS rates) and Brookmeyer and Crowley's method (median PFS).

Baseline tumor and plasma 1 *EGFR* mutation status (overall and by mutation subtype), in patients in the screened population who were evaluable for both samples, were compared with rates (percentages) and 95% CIs (Clopper-Pearson method) calculated for concordance, sensitivity, specificity, and positive- and negative-predictive value. Duplicate baseline plasma 1 and plasma 2 samples and baseline and progression plasma samples were compared, with rates and 95% CIs calculated.

RESULTS
=======

Patients
--------

Of 1060 patients screened from 13 countries, 1033 (97.5%) provided baseline tumor samples. Of these, *EGFR* mutation status could be determined for 859 patients (81.0%), and 118 patients (11.1%) were assigned an eligible *EGFR* mutation-positive status (mutation frequency, 13.7%) and enrolled in the study from September 8, 2010, to February 15, 2012; gefitinib treatment was started in 106 of these patients (FAS population) (Fig. [1](#F1){ref-type="fig"}). One additional patient of *EGFR* mutation-positive ineligible status was treated with gefitinib in error. Of the 201 patients (19%) for whom tumor *EGFR* mutation status could not be determined (unevaluable/unavailable), tissue was not provided from 27 patients (2.6%) who consented, and 174 patients (16.4%) could not be evaluated for *EGFR* mutation status (100 \[9.4%\] failed histopathology, 42 \[4.0%\] yielded insufficient DNA, 2 \[0.2%\] failed *EGFR* mutation analysis, and 30 \[2.8%\] were not shipped from the study site in time). A flow diagram of the accountability of tumor samples is presented in Figure [2](#F2){ref-type="fig"}.

![Patient flow diagram. ^a^All screened patients. Used to calculate the correlation between clinical characteristics and tumor *EGFR* mutation status and the comparison of *EGFR* mutation status between tumor DNA and plasma-derived circulating-free tumor DNA. ^b^One patient of *EGFR* mutation-positive ineligible status was treated in error and included in the evaluable-for-safety population. A total of 107 patients therefore started study treatment. ^c^Full analysis set population. Used to summarize efficacy data and for the comparison of *EGFR* mutation status in plasma and tumor samples. ^d^Number of patients with *EGFR* mutation-positive tumors (*n* = 118) used as the denominator for the percentage calculation. ^e^Number of patients started on treatment (*n* = 107) used as the denominator for the percentage calculation. EGFR, epidermal growth factor receptor. Reproduced, in part, from Douillard et al.^[@R17]^ *Br J Cancer* 2014;110:55--62.](jto-9-1345-g001){#F1}

![Tumor sample flow diagram. EGFR, epidermal growth factor receptor.](jto-9-1345-g002){#F2}

A total of 803 of 1060 screened patients (75.8%) provided duplicate baseline plasma 1 and 2 samples. Of these, *EGFR* mutation status could be determined using plasma 1 samples for 784 patients (74.0%), and 82 patients (7.7%) were assigned an *EGFR* mutation-positive status (mutation frequency, 10.5%). To achieve a similar measure of accuracy for analysis of plasma 2 samples and avoid unnecessary sample use, *EGFR* mutation status was determined for 224 plasma 2 samples whose corresponding plasma 1 sample was *EGFR* mutation status-known (all *EGFR* mutation-positive plasma 1 for whom plasma 2 was available, and a matched number of *EGFR* mutation-negative). Of these 224 plasma 2 samples chosen for analysis, 65 were assigned an *EGFR* mutation-positive status.

Demographics and baseline characteristics by *EGFR* mutation status derived from baseline tumor samples (FAS population), plasma 1 samples, and plasma 2 samples are presented in Supplementary Appendix Table 3 (Supplementary Digital Content 1, <http://links.lww.com/JTO/A638>) and were similar for all populations. Exon 19 deletions and L858R point mutations were the most commonly occurring mutations.

Comparison of *EGFR* Mutation Status in Matched Baseline Tumor and Plasma 1 Samples (Screened Population)
---------------------------------------------------------------------------------------------------------

Fewer patients were identified as having *EGFR* mutation-positive status using plasma 1-derived ctDNA (detection rate, 10.5%; 82 of 784 patients) than with tumor-derived DNA (detection rate, 13.7%, 118 of 859 patients). Due to technical problems with tumor samples (e.g., low tumor content, poor sample quality, insufficient quantity, poor/inappropriate fixation, no DNA), 201 of 1060 screened patients (19.0%) had an unknown *EGFR* mutation status; 12 of these patients were subsequently found to have a positive *EGFR* mutation status in their corresponding plasma 1 samples.

A total of 652 patients provided matched baseline tumor and plasma 1 samples that were evaluable for *EGFR* mutation status using both sample types. A comparison of *EGFR* mutation status between tumor and plasma 1 samples is shown in Table [1](#T1){ref-type="table"}. Concordance between baseline tumor and plasma 1 *EGFR* mutation status for patients evaluable for both samples was 94.3% (95% CI, 92.3--96.0), with a sensitivity of 65.7% (95% CI, 55.8--74.7) and specificity of 99.8% (95% CI, 99.0--100.0). Positive-predictive value and negative-predictive value of *EGFR* mutation status detection between baseline tumor and plasma 1 samples for patients evaluable for both samples are also shown. A comparison of *EGFR* mutation status by mutation subtype for baseline tumor and plasma 1 samples is presented in Table [2](#T2){ref-type="table"}. When analyzed by mutation subtype, concordance between baseline tumor and plasma 1 *EGFR* mutation status for patients evaluable for both samples was 96.5% (95% CI, 94.8--97.8) for exon 19 deletions and 97.9% (95% CI, 96.4--98.8) for L858R point mutations; sensitivity was 67.6% (95% CI, 55.5--78.2) and 61.8% (95% CI, 43.6--77.8), and specificity was 100.0% (95% CI, 99.4--100.0) and 99.8% (95% CI, 99.1--100.0), respectively.

###### 

EGFR Mutation Status Summary, Concordance, Sensitivity, Specificity, and Positive- and Negative-Predictive Value for Tumor vs. Plasma 1 Circulating-Free Tumor DNA Samples by EGFR Mutation Status (Screened Patients Evaluable for Both Samples, n = 652)

![](jto-9-1345-g003)

###### 

EGFR Mutation Status Summary, Concordance, Sensitivity, Specificity, and Positive- and Negative-Predictive Value for Tumor vs. Plasma 1 Circulating-Free Tumor DNA Samples by EGFR Mutation Subtype (Screened Patients Evaluable for Both Samples, n = 652)

![](jto-9-1345-g004)

Of the 547 patients considered to have an *EGFR* mutation-negative status by analysis of tumor DNA, one patient was considered to have an *EGFR* mutation-positive status by analysis of plasma 1 ctDNA, giving a false-positive rate of 0.2% (1 of 547). However, further investigation indicated that this was a false-positive result due to signal drift and was not a genuine positive amplification of the ctDNA (see Supplementary Appendix, Supplementary Digital Content 1, <http://links.lww.com/JTO/A638>, for further details).

Comparison of *EGFR* Mutation Status in Duplicate Baseline Plasma Samples (Screened Population)
-----------------------------------------------------------------------------------------------

Of the 803 screened patients who provided duplicate baseline plasma samples, 224 were evaluated and known for ctDNA *EGFR* mutation status. A total of 63 were identified with *EGFR* mutation-positive status in both samples, seven were *EGFR* mutation-positive in one plasma sample only, and 154 were negative in both samples (Table [3](#T3){ref-type="table"}). Concordance between duplicate baseline plasma sample *EGFR* mutation status (regardless of mutation status) for patients evaluable for both samples was 96.9% (95% CI, 93.7--98.7) (Table [3](#T3){ref-type="table"}). A summary of *EGFR* mutation status in duplicate baseline plasma samples by mutation subtype for patients evaluable for both samples is presented in Table [4](#T4){ref-type="table"}.

###### 

EGFR Mutation Status Comparisons for Plasma 1 vs Plasma 2 Circulating-Free Tumor DNA Samples by EGFR Mutation Status Summary and Concordance (Screened Patients Evaluable for Both Samples, n = 224)
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###### 

EGFR Mutation Status Comparisons for Plasma 1 vs Plasma 2 Circulating-Free Tumor DNA Samples by EGFR Mutation Status Summary by EGFR Mutation Subtype (Screened Patients Evaluable for Both Samples, n = 224)
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Comparison of *EGFR* Mutation Status in Baseline and Progression Plasma Samples (Screened Population)
-----------------------------------------------------------------------------------------------------

A total of 12 patients provided matched baseline (plasma 1) and progression plasma samples. *EGFR* mutation status concordance rate was 75.0% (95% CI, 42.8--94.5); mutation subtype results agreed in eight patients (caution is advised when interpreting these data due to small *n* numbers). Four patients had differences in *EGFR* mutation status: no mutations were detected in progression plasma ctDNA from three patients in which exon 19 deletions were detected in baseline plasma 1 ctDNA; one patient with an exon 19 deletion in baseline plasma 1 ctDNA acquired an additional T790M mutation in progression plasma ctDNA.

Post Hoc Analysis of Efficacy of Gefitinib According to Tumor and Plasma EGFR Mutation Status (FAS Population)
--------------------------------------------------------------------------------------------------------------

As of data cutoff, an objective response was seen in 74 of 106 patients in the FAS population whose tumors were *EGFR* mutation-positive, with an ORR of 69.8% (95% CI, 60.5--77.7) based on investigator assessment (*n* = 2 with complete response; *n* = 72 with partial response) (Fig. [3](#F3){ref-type="fig"}).

![Objective response rate according to *EGFR* mutation (and subtype) status for patients who were tumor *EGFR* mutation positive, tumor and plasma 1 *EGFR* mutation positive, and tumor *EGFR* mutation positive and plasma *EGFR* mutation negative. Reproduced, in part, from Douillard et al.^[@R17]^ *Br J Cancer* 2014;110:55--62.](jto-9-1345-g007){#F3}

For patients with matched tumor and plasma 1 samples, an ORR of 76.9% (95% CI, 65.4--85.5) was observed among those with a positive *EGFR* mutation result in both sample types (*n* = 50/65) (Fig. [3](#F3){ref-type="fig"}). An ORR of 59.5% (95% CI, 43.5--73.7) was observed among the 22 of 37 patients found to be mutation-positive by tumor but mutation-negative by plasma. Results were also consistent when analyzed by mutation subtypes: ORR for patients with both *EGFR* mutation-positive tumor and plasma 1 for exon 19 deletions (*n* = 45) 82.2% (95% CI, 68.7--90.7) and L858R (*n* = 20) 65.0% (95% CI, 40.8--84.6).

Median PFS for patients with matched tumor and plasma 1 samples that were positive for *EGFR* mutation in both sample types was 10.2 months (36 events; 95% CI, 8.5--12.5) (Table [5](#T5){ref-type="table"}), consistent with those patients who were *EGFR* mutation-positive by tumor, regardless of plasma ctDNA *EGFR* mutation status (median PFS, 9.7 mo \[95% CI, 8.5--11.0\]). When analyzed by mutation subtypes, median PFS for patients with matched tumor and plasma 1 samples that were positive in both sample types for exon 19 deletions (25 events) was 10.3 months (95% CI, 8.5--12.4), consistent with the PFS for patients whose tumors were exon 19 deletion-positive (41 events; median PFS, 9.6 mo; 95% CI, 8.0--11.0). There were an insufficient number of events to assess the PFS of patients with samples that were L858R mutation-positive (tumor or ctDNA).

###### 

Median PFS for Patients With Tumor and Plasma 1 Circulating-Free Tumor DNA Samples Overall and by EGFR Mutation Subtypes (FAS Population)

![](jto-9-1345-g008)

DISCUSSION
==========

The gefitinib follow-up measure study^[@R18]^ is, to our knowledge, the first prospective, large-scale study of first-line gefitinib to be conducted in Caucasian patients with *EGFR* mutation-positive advanced NSCLC. Previously published efficacy and tolerability results from the study show that first-line gefitinib is effective and well tolerated in this patient population.^[@R18]^ The preplanned and exploratory biomarker analyses reported here show a high rate of concordance for *EGFR* mutation status (including mutation subtypes) between tumor tissue DNA and plasma ctDNA and between duplicate plasma ctDNA samples. Tumor *EGFR* mutation status could not be determined (unevaluable/unavailable) for 19% of patient samples. Together, these results suggest that a single plasma-derived ctDNA sample may be considered appropriate for assessment of *EGFR* mutation status when tumor tissue is unavailable or exhausted.

The plasma ctDNA *EGFR* mutation analysis results reported here demonstrated 94.3% concordance, 99.8% specificity, and 65.7% sensitivity, an improvement on previous analysis of ctDNA, for example, in the IPASS study.^[@R5]^ This improvement may be due to a number of reasons, including different sample type (plasma versus serum), different DNA extraction method (the current study used a bespoke ctDNA extraction method), or a modified ARMS mutation detection kit. With regard to concordance between detection of *EGFR* mutations in matched tumor and plasma samples, a recent study of 111 Chinese patients with stage I--IV NSCLC reported 71.2% concordance, 35.6% sensitivity, and 95.5% specificity using enriched PCR and sequencing.^[@R25]^ Similarly, Yung et al.^[@R9]^ reported a specificity and sensitivity (using microfluidics digital PCR) of *EGFR* mutation status with ctDNA and matched tumor samples from 35 Chinese patients with NSCLC of 100% and 92%, respectively.

When considering ctDNA sample *EGFR* mutation status as patient selection for EGFR TKI therapy, the results we have reported here suggest that use of this alternative sample type may be appropriate in patients without available tumor samples, as patients with *EGFR* mutation-positive ctDNA, regardless of mutation subtype, had a similar ORR to patients with *EGFR* mutation-positive tumors (76.9% and 69.8%, respectively). A study of 50 samples (32 pleural fluid; 18 plasma) from Chinese patients with NSCLC previously treated with EGFR TKIs (line of therapy not stated) also found that an *EGFR* mutation-positive status detected by these surrogate samples was a significant and consistently good indicator of response to EGFR TKIs (pleural fluid-positive ORR 81.3% with direct sequencing, 72.7% with ARMS; plasma-positive ORR 80.0% with ARMS).^[@R15]^

It is widely accepted that there are challenges in *EGFR* mutation testing practice. In the past, this has been particularly evident in the Asia-Pacific region, where a lack of access and/or adoption of testing was a barrier to large-scale testing.^[@R26]^ A 2011 consensus meeting to discuss *EGFR* mutation testing in East Asia considered tissue acquisition and pre-test sample evaluation as important steps to increase specificity and sensitivity and to thus help standardize mutation test methodology in the region.^[@R26]^ Data generated from large-scale studies of *EGFR* mutation frequency, such as the PIONEER study,^[@R27]^ are confirming that large-scale testing across countries is feasible, can be standardized, and can result in a high analysis success rate. It is hoped that data generated from ongoing diagnostic studies such as ASSESS^[@R16]^ and IGNITE^[@R17]^ will add to this growing body of evidence. In addition, patient monitoring through ctDNA testing during treatment and at progression might provide important information on progression mechanisms. Our limited series of 12 patients showed that in one case a resistance mutation (T790M) was identified. Such information might be useful for managing patients with progression. The issue of re-biopsy at progression is presently a major concern and ctDNA testing could potentially be an alternative approach, as recently published^[@R28]^ and more generally discussed.^[@R29]^

A challenge for those undertaking testing is that mutation detection kits are often validated solely on tumor-derived DNA. In the future, kits for use on surrogate sample types such as cytology or plasma may become available as the body of evidence increases. As many patients with NSCLC attending clinic do not have tumor tissue samples available (10--15% from author's clinical experience), this could limit the number of patients able to benefit from the current mutation testing environment. Progress is being made, however, as highlighted by the Chinese State Food and Drug Administration's recent approval for the clinical use of three ADx-ARMS mutation tests (including *EGFR*) produced by Amoy Dx (Xiamen, China) for testing of fresh, frozen, and paraffin-embedded tissue as well as blood and plasma samples, so addressing the current area of unmet need in patients with unevaluable/unavailable tumor samples at diagnosis.

A conundrum challenging the NSCLC community is the apparent lack of detectable mutations in the ctDNA of some patients. As noted above, the *EGFR* mutation detection rate in the study reported here was 13.7% in tumor DNA and 10.5% in matched ctDNA; it is unclear whether this (commonly reported) lower detection rate in ctDNA is due to patient biology (tumor heterogeneity or biologic evolution of the disease) or technical limitations of current technologies (sampling, extraction, and mutation detection). To help minimize any ctDNA false-negative results due to technical difficulties, a highly sensitive mutation detection kit should be used, for example, ARMS technology,^[@R15]^ or one of the new more sophisticated techniques, for example, Beads, Emulsions, Amplification, and Magentics (BEAMing) or digital PCR. Indeed, the use of ARMS technology in the study reported here helped to achieve a 94.3% concordance and 65.7% sensitivity between matched tumor and plasma samples.

In light of these challenges/gaps in current knowledge, coupled with the unmet medical need in diagnosis, it is hoped that the results of this study, in conjunction with data from ongoing studies, will help to inform the NSCLC community about several aspects of mutation testing, including the use of sample types in diagnostic practice which are surrogates of tumor tissue when tissue is unavailable; *EGFR* mutation test processes and methodology; the use of multiple sample types in the assessment of *EGFR* mutation status; and the impact of *EGFR* mutation status on therapy choice. These data may help drive improvements in the *EGFR* mutation testing environment, ensuring that patients have access to testing and are treated appropriately on the basis of the molecular features of their disease. To date, there are no published guidelines for the use of ctDNA for *EGFR* mutation analysis in the absence of NSCLC tumor samples. Such a lack of formal direction has necessitated clinicians to either limit the use of this sample type to the research setting or form their own clinical perspective/opinion on the use of surrogate samples to ascertain mutation status. Therefore, although tumor tissue should be considered the preferred sample type for mutation analysis when available, the encouraging results from ctDNA analysis reported here may in the future help to address this current area of unmet need for those patients who do not have a tumor tissue sample, that is, their sample is unavailable or exhausted during diagnosis.

In summary, the high concordance, specificity, and sensitivity reported here between DNA and ctDNA *EGFR* mutation status demonstrates that *EGFR* mutation status can be accurately assessed using ctDNA. Although these results are encouraging and suggest that plasma is a suitable substitute for mutation analysis regardless of mutation subtype, tumor tissue should be considered the preferred sample type when available.
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